Jens Juul Holst
Jens Juul Holst
Professor of Medical Physiology, University of Copenhagen
Verified email at sund.ku.dk
TitleCited byYear
The physiology of glucagon-like peptide 1
JJ Holst
Physiological reviews 87 (4), 1409-1439, 2007
24482007
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
MA Nauck, MM Heimesaat, C Orskov, JJ Holst, R Ebert, W Creutzfeldt
The Journal of clinical investigation 91 (1), 301-307, 1993
15471993
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
M Zander, S Madsbad, JL Madsen, JJ Holst
The Lancet 359 (9309), 824-830, 2002
15092002
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, JJ Holst
The Journal of clinical investigation 101 (3), 515-520, 1998
13461998
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
MA Nauck, N Kleine, C Ørskov, JJ Holst, B Willms, W Creutzfeldt
Diabetologia 36 (8), 741-744, 1993
11701993
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
MB Toft-Nielsen, MB Damholt, S Madsbad, LM Hilsted, TE Hughes, ...
The Journal of Clinical Endocrinology & Metabolism 86 (8), 3717-3723, 2001
10072001
Antidiabetogenic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus
M Gutniak, C Ørkov, JJ Holst, B Ahrén, S Efendić
New England Journal of Medicine 326 (20), 1316-1322, 1992
9931992
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
T Vilsbøll, T Krarup, CF Deacon, S Madsbad, JJ Holst
Diabetes 50 (3), 609-613, 2001
9812001
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
CF Deacon, MA Nauck, M Toft-Nielsen, L Pridal, B Willms, JJ Holst
Diabetes 44 (9), 1126-1131, 1995
9521995
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
MA Nauck, U Niedereichholz, R Ettler, JJ Holst, C Ørskov, R Ritzel, ...
American Journal of Physiology-Endocrinology And Metabolism 273 (5), E981-E988, 1997
9181997
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
CF Deacon, AH Johnsen, JJ Holst
The Journal of Clinical Endocrinology & Metabolism 80 (3), 952-957, 1995
8911995
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations
ER Pearson, I Flechtner, PR Njølstad, MT Malecki, SE Flanagan, B Larkin, ...
New England Journal of Medicine 355 (5), 467-477, 2006
8812006
Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans
C Ørskov, L Rabenhøj, A Wettergren, H Kofod, JJ Holst
Diabetes 43 (4), 535-539, 1994
8381994
Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man
A Wettergren, B Schjoldager, PE Mortensen, J Myhre, J Christiansen, ...
Digestive diseases and sciences 38 (4), 665-673, 1993
7971993
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K Miyawaki, Y Yamada, N Ban, Y Ihara, K Tsukiyama, H Zhou, S Fujimoto, ...
Nature medicine 8 (7), 738, 2002
7912002
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
JJ Holst, J Gromada
American Journal of Physiology-Endocrinology And Metabolism 287 (2), E199-E206, 2004
7632004
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nystrom, MK Gutniak, Q Zhang, F Zhang, JJ Holst, B Ahrén, A Sjoholm
American Journal of Physiology-Endocrinology and Metabolism 287 (6), E1209-E1215, 2004
7172004
A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans
C Verdich, A Flint, JP Gutzwiller, E Naslund, C Beglinger, PM Hellstrom, ...
The Journal of Clinical Endocrinology & Metabolism 86 (9), 4382-4389, 2001
7142001
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin …
B Willms, J Werner, JJ Holst, C Orskov, W Creutzfeldt, MA Nauck
The Journal of Clinical Endocrinology & Metabolism 81 (1), 327-332, 1996
6221996
Glucagon-like peptide-1-(7–36) amide is transformed to glucagon-like peptide-1-(9–36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine …
L Hansen, CF Deacon, C Ørskov, JJ Holst
Endocrinology 140 (11), 5356-5363, 1999
6091999
The system can't perform the operation now. Try again later.
Articles 1–20